KRAS and cancer: Also, the cancer was already metastatic (stage IV) at diagnosis somewhat more often in patients with KRAS mutation than in other patient groups (KRAS G12C n = 12, 57%; other KRAS n = 31, 61%; other driver mutation n = 22, 43%; no driver mutations n = 61, 44%) indicating more aggressive disease.